A carregar...
Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence
Acute myeloid leukemia (AML) is a highly heterogeneous hematopoietic malignancy characterized by excessive proliferation and accumulation of immature myeloid blasts in the bone marrow. AML has a very poor 5-year survival rate of just 16% in the UK; hence, more efficacious, tolerable, and targeted th...
Na minha lista:
| Publicado no: | J Clin Med |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7563273/ https://ncbi.nlm.nih.gov/pubmed/32932888 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9092934 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|